TD Cowen Upgrades Stoke Therapeutics (NASDAQ:STOK) to “Outperform”

Stoke Therapeutics (NASDAQ:STOK) was upgraded by equities research analysts at TD Cowen from a “market perform” rating to an “outperform” rating in a report issued on Tuesday, MarketBeat reports.

Several other brokerages have also weighed in on STOK. Canaccord Genuity Group upped their target price on Stoke Therapeutics from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 target price on shares of Stoke Therapeutics in a research report on Friday, February 16th. Finally, JPMorgan Chase & Co. upped their target price on Stoke Therapeutics from $6.00 to $13.00 and gave the stock a “neutral” rating in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.63.

Stoke Therapeutics Trading Up 37.7 %

NASDAQ:STOK opened at $14.17 on Tuesday. The firm has a market capitalization of $632.69 million, a price-to-earnings ratio of -5.98 and a beta of 0.68. Stoke Therapeutics has a 1-year low of $3.35 and a 1-year high of $16.40. The business’s fifty day moving average price is $5.88 and its 200 day moving average price is $4.95.

Insider Transactions at Stoke Therapeutics

In related news, CFO Stephen J. Tulipano sold 4,116 shares of the stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the sale, the chief financial officer now owns 20,746 shares in the company, valued at approximately $126,550.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CFO Stephen J. Tulipano sold 4,116 shares of the stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the sale, the chief financial officer now owns 20,746 shares in the company, valued at approximately $126,550.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Barry Ticho sold 10,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $4.80, for a total value of $48,000.00. Following the sale, the insider now owns 6,981 shares of the company’s stock, valued at approximately $33,508.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 37,615 shares of company stock worth $212,852. 12.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in Stoke Therapeutics by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 1,648,502 shares of the company’s stock valued at $8,671,000 after purchasing an additional 17,814 shares in the last quarter. Barclays PLC increased its holdings in Stoke Therapeutics by 365.3% during the 4th quarter. Barclays PLC now owns 39,271 shares of the company’s stock valued at $206,000 after purchasing an additional 30,831 shares in the last quarter. Granahan Investment Management LLC increased its holdings in Stoke Therapeutics by 33.7% during the 4th quarter. Granahan Investment Management LLC now owns 1,137,887 shares of the company’s stock valued at $5,985,000 after purchasing an additional 286,686 shares in the last quarter. Bridgeway Capital Management LLC acquired a new stake in Stoke Therapeutics during the 4th quarter valued at $90,000. Finally, Birchview Capital LP increased its holdings in Stoke Therapeutics by 147.1% during the 4th quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock valued at $1,105,000 after purchasing an additional 125,000 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.